April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Visual Outcome in Myopic Choroidal Neovascularisation Following Anti-VEGF (Bevacizumab or Ranibizumab) Therapy Compared to Photodynamic Treatment (PDT) or Observation
Author Affiliations & Notes
  • B. Pal
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • S. Degli Esposti
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • J. DeZaeytijd
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • W. Rahman
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • F. Adatia
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • R. D. Hamilton
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • A. Tufail
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships  B. Pal, None; S. Degli Esposti, None; J. DeZaeytijd, None; W. Rahman, None; F. Adatia, None; R.D. Hamilton, None; A. Tufail, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2197. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      B. Pal, S. Degli Esposti, J. DeZaeytijd, W. Rahman, F. Adatia, R. D. Hamilton, A. Tufail; Visual Outcome in Myopic Choroidal Neovascularisation Following Anti-VEGF (Bevacizumab or Ranibizumab) Therapy Compared to Photodynamic Treatment (PDT) or Observation. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2197.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To analyse visual outcome in myopic choroidal neovascularisation following anti-VEGF therapy, photodynamic treatment (PDT) or observation.

Methods: : This is a retrospective cohort comparative study. This study was undertaken after local research and governance approval. The analysis of 51 case records with myopic macular degeneration was completed. These patients were categorised into three cohorts. This included Group A - observation only, Group B - PDT treatment and Group C - intravitreal anti-VEGF injection treatment (Bevacizumab or Ranibizumab). The visual outcomes, follow up period and number of treatments was recorded. Treatment was repeated when signs of activity of the choroidal neovascularisation was detected clinically, and on OCT or fluorescein angiogram. The mean follow up data for all the 3 groups was 2 years.

Results: : In the observation group A for 22 patients the mean follow up data was available for 27.4 months. The mean initial and final visual acuity was 6/24 and 6/36 respectively. In group B, with 8 patients undergoing PDT treatment, the mean follow up period was 35.5 months. The average number of PDT treatments was 2.38 lasers. The mean initial and final visual acuity in this group was 6/24 and 6/18 respectively. In group C, the 21 patients undergoing anti-VEGF treatment had mean follow up data for 19.4 months. Out of 21 patients, 16 patients were treated with Bevacizumab and 5 patients had Ranibizumab treatment. They required an average of 3.36 anti-VEGF injections. The mean initial and final visual acuity in this group was 6/18 and 6/15 respectively.

Conclusions: : The visual outcome was better for anti-VEGF treatment group than the PDT group. In comparison to the observation group, there was visual improvement in both the anti-VEGF and PDT groups. The limitation of the study was the retrospective nature of data collection and small numbers in each group.

Keywords: choroid: neovascularization • retina • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×